Xenon Pharmaceuticals (XENE) Interest Coverage Ratio (2013 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly Interest Coverage Ratio of 13.57 for Q1 2026, down 81.79% year-over-year from 74.53 in Q1 2025, and up 94.63% quarter-over-quarter from 252.92 in Q4 2025.
Xenon Pharmaceuticals (XENE) Interest Coverage Ratio (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Interest Coverage Ratio for 14 consecutive years, with 13.57 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 81.79% year-over-year to 13.57; the TTM figure through Mar 2026 stood at 49.87 (down 65.79% YoY), while the FY2025 annual figure was 1.08, up 57.17% from the prior year.
- Interest Coverage Ratio climbed to 13.57 in Q1 2026 per XENE's latest filing, from 252.92 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 1.5 in Q1 2022 and bottomed at 252.92 in Q4 2025.
- Historically, Interest Coverage Ratio has averaged 56.93 across 5 years, with a median of 19.4 in 2022.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio surged 94.63% — and 2023, when it slumped 1705.78%.
- Xenon Pharmaceuticals' Interest Coverage Ratio stood at 154.2 in 2022, then gained by 14.02% to 132.58 in 2023, then tumbled by 36.86% to 181.44 in 2024, then slumped by 39.39% to 252.92 in 2025, then surged by 94.63% to 13.57 in 2026.
- Business Quant data shows XENE's Interest Coverage Ratio at 13.57 in Q1 2026, 252.92 in Q4 2025, and 10.39 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - | -17.38 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.38 |
| Mar 31, 2026 | -13.57 |
| Dec 31, 2025 | -252.92 |
| Sep 30, 2025 | -10.39 |
| Jun 30, 2025 | -91.22 |
| Mar 31, 2025 | -7.47 |
| Dec 31, 2024 | -181.44 |
| Sep 30, 2024 | -6.64 |
| Jun 30, 2024 | -6.05 |
| Mar 31, 2024 | -4.95 |
| Dec 31, 2023 | -132.58 |
| Sep 30, 2023 | -4.38 |
| Jun 30, 2023 | -24.09 |
| Mar 31, 2023 | -27.01 |
| Dec 31, 2022 | -154.20 |
| Sep 30, 2022 | -19.40 |
| Jun 30, 2022 | -30.01 |
| Mar 31, 2022 | -1.50 |
| Dec 31, 2021 | -121.16 |
| Sep 30, 2021 | -27.32 |